Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Post by smallcapsteve2on Jun 21, 2020 2:11pm
196 Views
Post# 31174528

Revive Therapeutics And The Psychedelic Revolution

Revive Therapeutics And The Psychedelic Revolution

A massive psychedelics boom is already here.

In fact, with the potential to treat a wide range of mental and health issues for millions, it’s opening a wide range of opportunity for companies, like Revive Therapeutics (CSE: RVV) (OTC: RVVTF), which recently announced a $2.75 million acquisition of Psilocin Pharma Corp., a specialty psychedelic sciences company focused on the development of Psilocybin-based therapeutics for various medical needs.

Better still, Revive Therapeutics is investigating novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on the company’s wholly-owned patent-pending psilocybin formulations.

The best part – Revive Therapeutics’ psychedelics story has only just begun.

https://thedeepdive.ca/revive-therapeutics-and-the-psychedelic-revolution/

<< Previous
Bullboard Posts
Next >>